Bristol-Myers Squibb (BMY) is making a big push into artificial intelligence. The pharmaceutical giant announced a strategic agreement with Anthropic on Wednesday to deploy the company's Claude AI across its operations, aiming to speed up the discovery and development of new medicines.
The idea is to connect more than 30,000 employees with critical institutional knowledge using Anthropic's advanced AI capabilities. Think of it as giving every researcher, clinician, and manufacturing specialist a super-smart assistant that knows everything the company has ever learned about drug development. The partnership focuses on areas expected to deliver high impact, and it builds on over three years of AI investment at Bristol-Myers Squibb.
This isn't the company's only AI bet. Last week, Tempus AI Inc. (TEM) announced a new collaboration with Bristol-Myers Squibb aimed at improving clinical trial design. The two companies plan to use artificial intelligence, multimodal real-world data, and advanced data science tools to refine drug development strategies in oncology and neuroscience. Specifically, they'll use Tempus' AI-enabled analytical platform, Lens, to analyze a large library of de-identified patient records. The goal is to test trial assumptions, identify appropriate patient populations, and improve control group validation — all of which should strengthen Bristol-Myers Squibb's development portfolio.
For investors, the stock's movement is also tied to ETF flows. Bristol-Myers Squibb is a significant holding in several dividend and pharmaceutical ETFs. Here are the top three:
- Invesco S&P Ultra Dividend Revenue ETF (RDIV): 5.42% weight
- VanEck Pharmaceutical ETF (PPH): 4.64% weight
- iShares US Pharmaceutical ETF (IHE): 4.63% weight
Because BMY carries significant weight in these funds, any meaningful inflows or outflows for these ETFs will likely force automatic buying or selling of the stock. It's a reminder that sometimes a stock moves not because of company-specific news, but because of the mechanical actions of the funds that hold it.
As for Wednesday's price action, Bristol-Myers Squibb shares were up 0.12% at $58.38 at the time of publication.
